These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34229736)

  • 1. Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics.
    Koo BS; Eun S; Shin K; Yoon H; Hong C; Kim DH; Hong S; Kim YG; Lee CK; Yoo B; Oh JS
    Arthritis Res Ther; 2021 Jul; 23(1):178. PubMed ID: 34229736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning-based remission prediction in rheumatoid arthritis patients treated with biologic disease-modifying anti-rheumatic drugs: findings from the Kuwait rheumatic disease registry.
    Alsaber AR; Al-Herz A; Alawadhi B; Doush IA; Setiya P; Al-Sultan AT; Saleh K; Al-Awadhi A; Hasan E; Al-Kandari W; Mokaddem K; Ghanem AA; Attia Y; Hussain M; AlHadhood N; Ali Y; Tarakmeh H; Aldabie G; AlKadi A; Alhajeri H
    Front Big Data; 2024; 7():1406365. PubMed ID: 39421133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg.
    Ukalovic D; Leeb BF; Rintelen B; Eichbauer-Sturm G; Spellitz P; Puchner R; Herold M; Stetter M; Ferincz V; Resch-Passini J; Zwerina J; Zimmermann-Rittereiser M; Fritsch-Stork R
    Arthritis Res Ther; 2024 Feb; 26(1):44. PubMed ID: 38331930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis.
    Lee S; Kang S; Eun Y; Won HH; Kim H; Lee J; Koh EM; Cha HS
    Arthritis Res Ther; 2021 Oct; 23(1):254. PubMed ID: 34627335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
    Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
    Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
    Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
    Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
    Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan.
    Kondo M; Yamada H
    Mod Rheumatol; 2019 Nov; 29(6):928-935. PubMed ID: 30334661
    [No Abstract]   [Full Text] [Related]  

  • 13. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
    Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs.
    Vodencarevic A; Tascilar K; Hartmann F; Reiser M; Hueber AJ; Haschka J; Bayat S; Meinderink T; Knitza J; Mendez L; Hagen M; Krönke G; Rech J; Manger B; Kleyer A; Zimmermann-Rittereiser M; Schett G; Simon D;
    Arthritis Res Ther; 2021 Feb; 23(1):67. PubMed ID: 33640008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing patterns and clinical outcomes of biological disease-modifying anti-rheumatic drugs for rheumatoid arthritis in Spain.
    Martinez-Múgica C; Manso G
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8177-8184. PubMed ID: 32767346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis.
    Koo BS; Eun S; Shin K; Hong S; Kim YG; Lee CK; Yoo B; Oh JS
    Arthritis Res Ther; 2022 Oct; 24(1):233. PubMed ID: 36242075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.